Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With BeneFIX (Nonacog Alfa, Recombinant Factor IX) In Chinese Subjects With Hemophilia B

NCT00866606 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00866606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With BeneFIX (Nonacog Alfa, Recombinant Factor IX) In Chinese Subjects With Hemophilia B
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2009
Enrollment
35 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b